These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 18678432)

  • 1. Is there discrimination in access to therapy for HCV patients?
    Garattini S
    J Hepatol; 2008 Oct; 49(4):491-3. PubMed ID: 18678432
    [No Abstract]   [Full Text] [Related]  

  • 2. Market uptake of new antiviral drugs for the treatment of hepatitis C.
    Lettmeier B; Mühlberger N; Schwarzer R; Sroczynski G; Wright D; Zeuzem S; Siebert U
    J Hepatol; 2008 Oct; 49(4):528-36. PubMed ID: 18682313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economics of hepatitis C virus.
    Shah BB; Wong JB
    Clin Liver Dis; 2006 Nov; 10(4):717-34. PubMed ID: 17164114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C in 2012: On the fast track towards IFN-free therapy for hepatitis C?
    Wedemeyer H
    Nat Rev Gastroenterol Hepatol; 2013 Feb; 10(2):76-8. PubMed ID: 23296251
    [No Abstract]   [Full Text] [Related]  

  • 5. UNITAID can address HCV/HIV co-infection.
    von Schoen-Angerer T; Cohn J; Swan T; Piot P
    Lancet; 2013 Feb; 381(9867):628. PubMed ID: 23439101
    [No Abstract]   [Full Text] [Related]  

  • 6. Economic impact of extended treatment with peginterferon alpha-2a and ribavirin for slow hepatitis C virologic responders.
    Nakamura J; Toyabe SI; Aoyagi Y; Akazawa K
    J Viral Hepat; 2008 Apr; 15(4):293-9. PubMed ID: 18307591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Because fee settlement means are not widely known. Deficits in hepatitis C therapy].
    MMW Fortschr Med; 2003 May; 145(19):55. PubMed ID: 12813986
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
    Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
    J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Access to peginterferon plus ribavirin therapy for hepatitis C in Romania between 2002-2009.
    Gheorghe L; Pascu O; Ceausu E; Csiki IE; Iacob S; Caruntu F; Simionov I; Vadan R
    J Gastrointestin Liver Dis; 2010 Jun; 19(2):161-7. PubMed ID: 20593049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy for hepatitis C infection.
    Newman TB
    N Engl J Med; 1999 Apr; 340(15):1207; author reply 1208-9. PubMed ID: 10206843
    [No Abstract]   [Full Text] [Related]  

  • 11. Economic burden associated with patients diagnosed with hepatitis C.
    McCombs JS; Yuan Y; Shin J; Saab S
    Clin Ther; 2011 Sep; 33(9):1268-80. PubMed ID: 21840056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The multifaceted functions of ribavirin: antiviral, immunomodulator, or both?
    Mondelli MU
    Hepatology; 2014 Oct; 60(4):1126-9. PubMed ID: 24753082
    [No Abstract]   [Full Text] [Related]  

  • 13. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
    Yu ML; Dai CY; Huang JF; Chuang WL
    Hepatology; 2008 Sep; 48(3):1019-20; author reply 1020-1. PubMed ID: 18756469
    [No Abstract]   [Full Text] [Related]  

  • 14. Delaying HCV treatment in HIV-positive patients.
    Carter M
    IAPAC Mon; 2005 May; 11(5):147. PubMed ID: 16201045
    [No Abstract]   [Full Text] [Related]  

  • 15. Prescribing practices for the treatment of hepatitis C in a Veterans Affairs medical center.
    Mangin EF; Jones WN
    Am J Health Syst Pharm; 2004 Jul; 61(14):1479-82. PubMed ID: 15332696
    [No Abstract]   [Full Text] [Related]  

  • 16. Can genetic variations predict HCV treatment outcomes?
    Selzner N; McGilvray I
    J Hepatol; 2008 Oct; 49(4):494-7. PubMed ID: 18692270
    [No Abstract]   [Full Text] [Related]  

  • 17. [Assessment and monitoring of patients with chronic hepatitis C on antiviral therapy--state of the art in 2003].
    Simon K; Szymczak A
    Pol Arch Med Wewn; 2004 Jul; 112(1):891-8. PubMed ID: 15526854
    [No Abstract]   [Full Text] [Related]  

  • 18. [Genotype 1 superresponder treat for only 24 weeks].
    MMW Fortschr Med; 2005 Dec; 147(51-52):69. PubMed ID: 16402717
    [No Abstract]   [Full Text] [Related]  

  • 19. Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia.
    Bruchfeld A; Lindahl K; Stahle L; Schvarcz R
    J Hepatol; 2006 Feb; 44(2):432-3; author reply 433. PubMed ID: 16338023
    [No Abstract]   [Full Text] [Related]  

  • 20. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
    Lukasiewicz E; Hellstrand K; Westin J; Ferrari C; Neumann AU; Pawlotsky JM; Schalm SW; Zeuzem S; Veldt BJ; Hansen BE; Verhey-Hart E; Lagging M
    Hepatology; 2007 Jan; 45(1):258-9. PubMed ID: 17187414
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.